Skip to content

PA · ERF.PA · MEDICAL - DIAGNOSTICS & RESEARCH

Eurofins Scientific SE (ERF.PA) intrinsic value and stock valuation

$85.30as of 2026-11-21 · Mkt cap 10.66B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Eurofins Scientific SE DCF and intrinsic value

InvestorsCraft values ERF.PA with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ERF.PA’s statements →

Eurofins Scientific SE Graham Number

Graham Number: $34.35d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Diagnostics & Research Luxembourg City 1526 eurofins.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$7.3B+6.1% 5y CAGRd
20112025
Net income
$475M-2.5% 5y CAGRd
20112025
Free cash flow
$535M-9.2% 5y CAGRd
20112025
Total equity
$3.58B-0.8% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$7.3B$6.95B$6.51B$6.71B$6.72B
Operating income$793M$726.2M$546.8M$783.2M$1.28B
Net income$475M$406.4M$310.3M$610.2M$782.6M
EPSd$2.54M$2.09M$1.57M$3.07M$3.9M
Operating cash flow$1.3B$1.32B$1.02B$1.14B$1.51B
Capital expenditure-$-760M-$-528.4M-$-550.1M-$-660.2M-$-519.5M
Free cash flow$535M$790.5M$467.8M$476.1M$990.3M
Total assets$11B$10.9B$10.9B$10.1B$9.33B
Total debt$5.43B$3.61B$3.93B$3.33B$2.75B
Net debt$4.64B$3B$2.71B$2.84B$2.24B
Total equity$3.58B$5.38B$5.14B$4.85B$4.68B
Cash and short-term investments$791M$613.9M$1.22B$486.6M$515.3M
Income statement
20252024202320222021
Revenue$7.3B$6.95B$6.51B$6.71B$6.72B
Cost of revenue$6.5B$2.24B$5.89B$2.23B$2.15B
Gross profit$793M$4.71B$620.4M$4.49B$4.57B
Research and development expenses$0.00$0.00$0.00$0.00$0.00
Selling, general and administrative expenses$0.00$0.00$73.6M$39.4M$60.3M
Other expenses$0.00$3.99B$0.00$3.66B$3.24B
Operating expenses$0.00$3.99B$73.6M$3.7B$3.3B
Cost and expenses$6.5B$6.22B$5.97B$5.93B$5.45B
Interest income$35M$19.3M$11.6M$2.2M$0.00
Interest expense$166M$150.8M$129.4M$105.6M$172.6M
Depreciation and amortization$630M$691.4M$664.3M$607.2M$389.9M
Ebitda$1.45B$1.38B$1.22B$1.47B$1.75B
Operating income$793M$726.2M$546.8M$783.2M$1.28B
Total other income/expenses, net-$-139M-$-171.6M-$-123.5M-$-3.2M-$-218.7M
Income before tax$654M$554.6M$423.3M$780M$1.06B
Income tax expense$181M$149.1M$115.5M$174.2M$273.6M
Net income$475M$406.4M$310.3M$610.2M$782.6M
Weighted average shares outstanding$180M$190.6M$192.9M$192.5M$191.5M
Weighted average diluted shares outstanding$187M$194.5M$197.9M$199M$200.6M
Balance sheet
20252024202320222021
Cash and short-term investments$791M$613.9M$1.22B$486.6M$515.3M
Net receivables$1.54B$1.51B$1.62B$1.6B$1.58B
Inventory$139M$141.9M$139M$145.6M$154.2M
Total current assets$2.65B$2.45B$3.07B$2.31B$2.32B
Property, plant and equipment, net$2.76B$2.56B$2.3B$2.17B$1.83B
Goodwill and intangible assets$5.35B$5.63B$5.35B$5.44B$5.01B
Long-term investments$105M$117.2M$83.6M$83.6M$81.7M
Total non-current assets$8.33B$8.44B$7.82B$7.77B$7.01B
Total assets$11B$10.9B$10.9B$10.1B$9.33B
Accounts payable$678M$645.9M$600.2M$647.7M$627.6M
Short-term debt$727M$478.8M$601M$213.8M$253.9M
Deferred revenue$217M$0.00$192.8M$184.2M$0.00
Total current liabilities$2.43B$2.11B$2.12B$1.77B$1.86B
Long-term debt$4.71B$3.13B$3.33B$3.11B$2.5B
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$4.97B$3.39B$3.63B$3.46B$2.8B
Capital lease obligations$0.00$607.5M$578.8M$527.6M$538.9M
Total liabilities$7.4B$5.5B$5.75B$5.23B$4.66B
Common stock$2M$1.9M$1.9M$1.9M$1.9M
Retained earnings$3.02B$2.69B$2.39B$2.33B$1.96B
Accumulated other comprehensive income (loss)-$-247M$2.95B$1.74B$2.46B$2.68B
Total equity$3.58B$5.38B$5.14B$4.85B$4.68B
Total investments$105M$117.4M$83.6M$83.6M$81.7M
Total debt$5.43B$3.61B$3.93B$3.33B$2.75B
Net debt$4.64B$3B$2.71B$2.84B$2.24B
Cash flow statement
20252024202320222021
Net income$475M$554.6M$310.3M$780M$1.06B
Depreciation and amortization$630M$596.9M$565M$504.4M$450.7M
Stock-based compensation$0.00$138.3M$122.6M$136.1M$131M
Change in working capital$51M$51.4M-$-75.7M$33M-$-6.6M
Accounts receivable$0.00$37.2M-$-20M-$-9M-$-109.6M
Inventory$0.00$3.6M$11M$8.6M$2.8M
Accounts payable$0.00-$-25.9M-$-41.4M$20.1M$85.6M
Net cash provided by operating activities$1.3B$1.32B$1.02B$1.14B$1.51B
Investments in property, plant and equipment-$-835M-$-453.6M-$-478.1M-$-660.2M-$-519.5M
Acquisitions, net-$-250M-$-344.3M-$-150.8M-$-214.7M-$-532.7M
Net cash used for investing activities-$-1.09B-$-846.5M-$-681.1M-$-855.9M-$-1.03B
Common stock issued$397M$200K$8M$14.6M$35.8M
Common stock repurchased-$-940M-$-271.9M-$-55.8M-$-15.8M-$-3.6M
Dividends paid-$-110M-$-95.6M-$-191.9M-$-192.1M-$-129.7M
Net cash used for financing activities$13M-$-1.09B$413.6M-$-311.3M-$-910.3M
Net change in cash$260.4M-$-607.7M$737.7M-$-31.8M-$-395.5M
Cash at end of period$791M$613.2M$1.22B$483.2M$515M
Operating cash flow$1.3B$1.32B$1.02B$1.14B$1.51B
Capital expenditure-$-760M-$-528.4M-$-550.1M-$-660.2M-$-519.5M
Free cash flow$535M$790.5M$467.8M$476.1M$990.3M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Eurofins Scientific SE

        Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. The company offers a portfolio of approximately 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability, and purity of various products. It provides services such as agro-science, including biological assessment, consumer and human, and environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, such as product inspection, auditing, certification, training and consultation of food, consumer products, and healthcare and cosmetics; biopharma, and clinical diagnostics. In addition, the company offers consumer product testing, which include product compliance and audit, testing, certifications and approvals, inspections, training courses, and digital media and cyber security for various industries; cosmetics and personal care; environment testing, including water, air, soil, waste, and other products testing; and food and feed testing that include allergen, GMO, grain, meat, nano material, pesticides, and residual DNA testing. Further, it offers audit and certification, authenticity, carbohydrates, consulting, dioxins and POPs, food irradiation, labelling, law, heavy metals, identity preservation, mealtime, molecular and microbiology, mycotoxins, nutritional analyses, organic containments, packaging/migration, radioactivity, rapidest, sensorsy and consumer research, trainings, veterinary drug residues, and vitamins services. Additionally, the company provides forensic, genomic, maritime, materials and engineering, REACH, and technologies services. It operates approximately 900 laboratories in 54 countries. The company was founded in 1987 and is headquartered in Luxembourg City, Luxembourg.

        CEO
        Gilles G. Martin
        Employees
        62.7K
        Beta
        0.85

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of Eurofins Scientific SE (ERF.PA)?

        InvestorsCraft does not currently publish an intrinsic value for ERF.PA. How the IC value is calculated.

        Is ERF.PA undervalued?

        InvestorsCraft does not publish an undervaluation signal for ERF.PA at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.